VVOSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Vivos Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.13+0.00 (+2.90%)
Close on Oct 19, 2026
- Market cap
- $2.39M
- P/E (TTM)
- –
- Dividend yield
- –
Vivos Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Service [Member] | $15.32M | $13.45M | $10.96M | $9.16M | $6.47M | $6.62M | $7.16M | $7.49M | $7.42M | $7.19M | $7.53M | $7.70M | 73.3% | +136.7% |
| Sleep Testing Services [Member] | $9.56M | $8.01M | $6.04M | $4.06M | $1.82M | $1.30M | $1.28M | $1.26M | $1.24M | $1.23M | $1.19M | $1.14M | 45.7% | +424.2% |
| Product [Member] | $5.58M | $6.11M | $6.49M | $8.16M | $7.92M | $8.01M | $7.87M | $7.09M | $6.60M | $6.17M | $6.27M | $6.81M | 26.7% | -29.5% |
| Treatment Centers [Member] | $3.60M | – | $2.18M | – | – | – | – | – | – | – | – | – | 17.2% | – |
| Sponsorship Seminar Other [Member] | $895.00K | $1.34M | $1.22M | $2.47M | $2.52M | $2.14M | $1.94M | $929.00K | $736.00K | $650.00K | $676.00K | $814.00K | 4.3% | -64.5% |
| Billing Intelligence Services [Member] | $588.00K | $649.00K | $686.00K | $751.00K | $773.00K | $796.00K | $840.00K | $880.00K | $892.00K | $898.00K | $887.00K | $884.00K | 2.8% | -23.9% |
| VIP [Member] | $187.00K | $305.00K | $491.00K | – | – | – | – | $3.75M | $3.80M | $3.54M | $3.92M | $4.43M | 0.9% | – |
| Center Revenue [Member] | – | – | – | – | – | – | – | – | – | – | $189.00K | $192.00K | – | – |
| Appliance Sales To V I P [Member] | – | – | – | – | – | – | – | – | – | – | $6.08M | $6.62M | – | – |
| Myofunctional Therapy Services [Member] | – | – | – | $653.00K | $595.00K | $582.00K | $609.00K | $676.00K | $757.00K | $868.00K | $861.00K | $966.00K | – | – |
| Appliances [Member] | – | – | – | $4.81M | $4.99M | $5.54M | $5.60M | $6.43M | $6.04M | $5.72M | $6.08M | – | – | – |
| Guides [Member] | – | – | – | $3.35M | $2.94M | $2.48M | $2.27M | – | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Vivos Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.